การประดิษฐ์มุ่งตรงต่อองค์ประกอบทางเภสัชกรรมซึ่งมีอย่างน้อยหนึ่งชนิดของสารประกอบ FGF-21(ไฟโบรบลาสต์โกรทแฟกเตอร์ 21), อย่างน้อยหนึ่งชนิดของอะโกนิสต์ของ GLP-1R (รีเซป เตอร์สำหรับเพปไทด์ที่คลายกับกลูคากอน 1) และโดยทางเลือกแล้วอย่างน้อยหนึ่งชนิดของยารักษา โรคเบาหวาน และ/หรือ อย่างน้อยหนึ่งชนิดของตัวยับยั้งของ DPP-4 (ไดเพปทิดิลเพปทิเดส-4) เพื่อ การรักษาของอย่างน้อยหนึ่งกลุ่มอาการเกี่ยวกับเมแทบอลิก และ/หรือ โรคท่อเลือดแดงและหลอด เลือดแดงแข็ง (atherosclerosis), โดยเฉพาะอย่างยิ่งโรคเบาหวาน, ภาวะเลือดมีสารไขมันผิดปกติ (dyslipidemia), โรคอ้วน และ/หรือ อะดิโพซิทาส(adipositas) The invention is directed towards the pharmaceutical composition which contains at least one compound. FGF-21 (fibroblast growth factor 21), at least one type of agonist of GLP-1R (receptor for peptide loosened with glucagon 1). Optionally, at least one diabetes drug and / or at least one DPP-4 inhibitor (dipeptidyl peptidase-4) for treatment of at least one. Metabolic syndrome and / or atherosclerosis, especially diabetes mellitus, hyperlipidemia. (dyslipidemia), obesity and / or adipositas.
Claims (1)
1. องค์ประกอบทางเภสัชกรรมซึ่งมีอย่างน้อยหนึ่งสารประกอบ FGF-21 (ไฟโบรบลาสต์โกรท แฟกเตอร์ 21) และอย่างน้อยหนึ่งอะโกนิสต์ของ GLP-1R (รีเซปเตอร์สำหรับเพปไทด์ที่คล้ายกับกลูคา กอน 1)1. A pharmaceutical component, which contains at least one compound FGF-21 (fibroblast growth factor 21) and at least one GLP-1R agonist (receptor for peptide that Similar to glucagon 1)
TH1201003617A2011-01-21
Pharmaceutical components for the treatment of metabolic syndrome.
TH130088B
(en)
COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
Compounds derived from cyclic azabenzimidazole, activators of amp-activated protein kinase; pharmaceutical composition that includes them; and its use for treatment or disease such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and hypertension.
COMPOUNDS DERIVED FROM ESPIROCROMANONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT METABOLIC SYNDROME, FAT LIVER, HYPERLIPEMIA, OBESITY, DIABETES, BULIMIA, MALIGNO NEOPLASM OR INFECTIOUS DISEASES.
Glucagon analogs exhibiting agonist activity at the glusose-dependent insulinotropic peptide receptor (gip): pharmaceutical composition; and method to reduce weight gain or induce weight loss, particularly for the treatment of obesity.
Compounds derived from diaminocarboxamide and diaminocarbonitrile pyrimidines, such as jnk kinase inhibitors; pharmaceutical composition; in vitro inhibition method; and its use in the treatment or prevention of fibrotic liver disorders, diabetes or metabolic syndrome leading to fibrotic liver disorders.
Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes.
Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
COMPOUNDS DERIVED FROM 2-OXO-PIRIDIN-1 (2H) -IL-TIAZOL, IMIDAZOL OR THIOFEN-CARBOXAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF A DISEASE MEDIATED BY ESTEAROIL-COA-DESATURASA, SUCH AS METABOLIC SYNDROME, HYPERTENSION AND DIABETES
COMPOUNDS DERIVED FROM SUBSTITUTED BENZAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DIABETES, INTOLERANCE TO GLUCOSE, DISLIPIDEMIA, HYPERTENSION, OBESITY.
Compounds derived from (pyridin- or pyrimidin-) piperidine, gpr119 agonists; pharmaceutical composition; and its use for the treatment of type I diabetes, type II diabetes and related diseases such as metabolic syndrome, dyslipidemia and insulin resistance.
COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.
Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct
COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.